US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)

News
Article

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

The FDA logo on a laptop computer. Image credit: ©monticellllo – stock.adobe.com

The FDA comments in the CRL were not related to safety or efficacy, but a statistical matter pertaining to proposed labelling language for the product. Image credit: ©monticellllo – stock.adobe.com

Astellas Pharma Inc. announced the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for avacincaptad pegol intravitreal solution (Izervay). In the November 15 CRL, the FDA stated it cannot approve a supplemental New Drug Application in its present form. Izervay had an expected Prescription Drug User Fee Act (PDUFA) date of November 19.

In a press release, Astellas noted that the FDA comments in the CRL were not related to the safety, efficacy or risk of use for Izervay. The lack of approval is instead related to a statistical matter pertaining to proposed labelling language for the product.

The CRL was sent in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), which sought to include positive 2 year data in the US Prescribing Information. This data was gathered from results of the GATHER2 Phase 3 clinical trial, which evaluated the safety and efficacy of monthly and every other month dosing.

The company will be seeking further clarification from the FDA and plans on working with the agency to quickly address its feedback.

“Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated statistically significant slowing of GA across 2 pivotal Phase 3 studies,” said Marci English, senior vice president of Biopharma and Ophthalmology Development for Astellas Pharma, in the release. “While this is a disappointment for patients and physicians who rely on Izervay for the management of a chronic, progressive disease that can lead to irreversible vision loss, Astellas is unwavering in our commitment to the ophthalmology space and will continue to work with the FDA to advance solutions for those suffering from GA.”’

Izervay was approved by the US FDA on August 4, 2023 for the treatment of GA secondary to AMD.

Reference
1. Astellas Provides Update on IZERVAY™ (avacincaptad pegol intravitreal solution) Supplemental New Drug Application. News release. Astellas Pharma Inc. Published November 19, 2024. Accessed 19 November, 2024.


Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.